A randomised controlled trial of atomoxetine for adults with Attention Deficit Hyperactivity Disorder (ADHD)

A randomised controlled trial of atomoxetine vs placebo for attentional lapses in adults with attention deficit hyperactivity disorder (ADHD)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000432011

Enrollment

Registered

2010-05-27

Start date

2010-06-04

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Atomoxetine is an established treatment for ADHD. Despite its routine use, little is understood how it influences brain functioning. This study will test the effect of atomoxetine treatment on a range of brain functions relevant to ADHD.

Interventions

Atomoxetine capsules (daily dose ranging from 60mg-120mg) for 10 weeks. Starting dose is 60mg daily for all participants. Dose may be increased after 2 weeks to 90mg or 120 mg depending on individual clinical response as judged by clinical assessment and rating scales.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

Aged at least 18 years Diagnosis of ADHD

Exclusion criteria

1. Current or past diagnosis of psychotic disorders, pervasive development disorders, intellectual impairment, 2. History of serious neurologic illnesses including stroke, brain tumours, head trauma, multiple sclerosis, epilepsy, movement disorders or migraine in treatment 3. drug dependency on alcohol or illicit substances 4. Pregnancy or breast feeding

Outcome results